Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:CING NASDAQ:LPTX NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.01-2.4%$1.06$0.98▼$3.92$3.58M1.11191,372 shs520,693 shsCINGCingulate$5.37-3.6%$4.33$1.80▼$20.83$28.67M-0.79101,322 shs111,977 shsLPTXLeap Therapeutics$0.37+2.3%$0.35$0.22▼$4.79$14.80M-0.28491,725 shs428,976 shsUPXIUpexi$6.41-4.3%$8.12$1.90▼$22.57$254.03M-0.5811.28 million shs12.94 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma+0.98%-0.96%-0.96%-12.29%-71.33%CINGCingulate-2.79%+18.01%+37.87%+28.34%+1,436.98%LPTXLeap Therapeutics+1.77%+2.06%+15.60%-9.13%-84.12%UPXIUpexi-12.99%-7.71%-33.00%-50.44%-19.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma2.0949 of 5 stars3.53.00.00.00.60.01.3CINGCingulate2.5848 of 5 stars3.55.00.00.00.60.80.6LPTXLeap Therapeutics1.9494 of 5 stars3.02.00.00.02.60.01.3UPXIUpexi2.3164 of 5 stars3.51.00.00.02.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.00Buy$14.001,286.14% UpsideCINGCingulate 3.00Buy$26.00384.17% UpsideLPTXLeap Therapeutics 2.00Hold$3.38823.65% UpsideUPXIUpexi 3.00Buy$16.00149.61% UpsideCurrent Analyst Ratings BreakdownLatest CANF, UPXI, CING, and LPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.005/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.30N/AN/A$1.76 per share0.57CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AUPXIUpexi$26M9.35N/AN/A$6.24 per share1.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest CANF, UPXI, CING, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A8/11/2025Q2 2025LPTXLeap Therapeutics-$0.29N/AN/AN/AN/AN/A5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACINGCingulate0.161.871.87LPTXLeap TherapeuticsN/A2.412.41UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CINGCingulate41.31%LPTXLeap Therapeutics30.46%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CINGCingulate5.27%LPTXLeap Therapeutics7.50%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCINGCingulate205.15 million4.02 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableCANF, UPXI, CING, and LPTX HeadlinesRecent News About These CompaniesUpexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three MonthsJuly 21 at 8:00 AM | globenewswire.comUpexi Shares Slump After $50M Private Placement Offering ClosesJuly 17, 2025 | marketwatch.comUpexi call volume above normal and directionally bullishJuly 17, 2025 | msn.comUpexi Shares Jump After Securing $150 Million in Convertible Notes Backed by SolanaJuly 17, 2025 | msn.comUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15, 2025 | manilatimes.netMUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15, 2025 | globenewswire.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private ...July 13, 2025 | seekingalpha.comUpexi raises $200M to boost its Solana treasuryJuly 12, 2025 | msn.comUpexi prices $200M private placement of common stock and convertible notesJuly 11, 2025 | msn.comSOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury StrategyJuly 11, 2025 | finance.yahoo.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq RulesJuly 11, 2025 | globenewswire.comUpexi (NASDAQ:UPXI) Trading 26.7% Higher - Time to Buy?July 9, 2025 | marketbeat.comUpexi, Inc. (UPXI) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | MorningstarJune 27, 2025 | morningstar.comMUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - NasdaqJune 27, 2025 | nasdaq.comSolana-Focused Upexi to Tokenize Shares; Added 56K SOL to HoldingsJune 26, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening BellJune 26, 2025 | theglobeandmail.comUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell PlatformJune 26, 2025 | quiverquant.comQUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening BellJune 26, 2025 | globenewswire.comSolana Treasury Firm Upexi Falls After Insider Sales FilingJune 25, 2025 | bloomberg.comNews Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC FilingsJune 25, 2025 | decrypt.coDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Datadog Joins S&P 500, Triggering a New Wave of UpsideBy Gabriel Osorio-Mazilli | July 7, 2025View Datadog Joins S&P 500, Triggering a New Wave of UpsideCANF, UPXI, CING, and LPTX Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.01 -0.03 (-2.42%) Closing price 04:00 PM EasternExtended Trading$1.01 0.00 (0.00%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Cingulate NASDAQ:CING$5.37 -0.20 (-3.59%) Closing price 04:00 PM EasternExtended Trading$5.33 -0.04 (-0.74%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Leap Therapeutics NASDAQ:LPTX$0.37 +0.01 (+2.30%) Closing price 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.99%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Upexi NASDAQ:UPXI$6.41 -0.29 (-4.33%) Closing price 04:00 PM EasternExtended Trading$6.39 -0.02 (-0.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
